Nucleome

Nucleome Therapeutics is decoding the dark matter of the human genome to discover new ways to treat diseases. Currently, we are applying our platform technology to various cell types, including lymphocytes. We are committed to building a robust pipeline of drug assets that utilize corresponding biomarkers in diseases with clear unmet needs, such as systemic lupus erythematosus and rheumatoid arthritis.